Will long-COVID activists, especially practitioner-patients, finally force healthcare systems, clinicians and medical researchers to confront post-viral and similar chronic syndromes they have shrugged off for decades? In keeping with our mission, will a focused response by healthcare systems and researchers to post-COVID syndrome help illuminate the invisible epidemic of autoimmune and autoinflammatory disorders?
The emergence of post-COVID syndrome shines new light on the old problem of post-viral syndromes In Part 1, we discussed how the rise of long covid shines new light on chronic post-viral disorders long ignored by researchers and clinicians. But this issue didn’t just appear with the SARS-COV-2 COVID-19 pandemic.
First 2021 post in our series of B2B thought leadership interviews with visionary digital health entrepreneurs working to improve care of chronic conditions. In keeping with our mission, we particularly care about chronic immunoinflammatory disorders (CIIDs), e.g., autoimmune and autoinflammatory diseases. Bonnie and Ellen were happy to finally interview digital
Welcome to our B2B Thought Leadership series! We are delighted to start with a 2-part post from our interview with Bill Conlan, founder and CEO of CrossBridge. CrossBridge is a Software as a Service (SaaS) platform using data analytics to bridge care coordination gaps between healthcare payers and specialty provider
See Part 1 for how Bonnie met Bill Conlan pre-CrossBridge and for background on his entrepreneurial track record. That background includes SaaS platforms, analytics and the migration from fee-for-service (FFS) to value-based payments (VBP). Part 1 also lays out the challenges Bill saw for specialty practices in chronic disease management.
Dr Bonnie 360 interviews Chase Spurlock, PhD, founder and CEO of Decode Health on AI analytics in COVID and chronic inflammatory disease.
A continuation of Part 1. One of our B2B thought leadership interviews with digital health entrepreneurs working to improve the care of chronic conditions. We care particularly about chronic immunoinflammatory disorders (CIIDs), e.g., autoimmune and autoinflammatory diseases. This continues our interview with the CEO of Oshi Health, Sam Holliday. Oshi
On GI practice, beta risk, digital health, VBP and chronic care Another in our new series of B2B thought leadership interviews with visionary entrepreneurs applying digital tools to improve care of chronic immunoinflammatory disorders (CID), including autoimmune and autoinflammatory diseases. We were delighted to speak with Dr Lawrence R. Kosinski,
